In particular, ccRCC patients with low TCF19 mRNA levels had longer overall survival as compared to those with high TCF19 mRNA expression (Figure 1C), which was based on the UALCAN online database. This evidence concerns the gene TCF19 and nonpapillary renal cell carcinoma.